Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
ApexOnco Front Page
Recent articles
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
The company is stepping back in second-line breast cancer.
